Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where M. Antònia Vilaseca is active.

Publication


Featured researches published by M. Antònia Vilaseca.


Pediatrics | 2004

Hyperlactatemia in Human Immunodeficiency Virus–Uninfected Infants Who Are Exposed to Antiretrovirals

Antoni Noguera; Clàudia Fortuny; Carmen Muñoz-Almagro; Emília Sánchez; M. Antònia Vilaseca; Rafael Artuch; Jordi Pou; Rafael Jiménez

Objective. Exposure to nucleoside analogues in fetal or early life has been associated with rare clinically significant mitochondrial toxic effects, mainly neurologic symptoms. Lactate (LA) measurements have been used to monitor nucleoside-related mitochondrial toxicity. Our aim was to determine the prevalence, clinical evolution, and risk factors for hyperlactatemia in our cohort of human immunodeficiency virus (HIV)-uninfected children who were exposed to antiretrovirals. Methods. We conducted a prospective observational study of 127 HIV-uninfected infants who were born to HIV-infected women. Clinical symptoms suggesting mitochondrial dysfunction were analyzed in routine follow-up, and LA and alanine plasma levels were obtained at 6 weeks, 3 months, 6 months, and 12 months in all patients. Elevated alanine levels, together with hyperlactatemia, suggest chronic mitochondrial injury. Results. Most (85%) women received highly active antiretroviral therapy (HAART) during pregnancy (mean duration: 31 weeks) and zidovudine during labor (93%). Most (96%) children received zidovudine alone. Hyperlactatemia with hyperalaninemia was detected in 63 children in at least 1 of the measurements. Mean LA levels were significantly higher in children who were exposed to nucleoside analogue reverse transcriptase inhibitors than in control subjects (2.88 vs 1.61 at 6 weeks, 2.78 vs 1.49 at 3 months, 1.89 vs 1.39 at 6 months, and 1.71 vs 1.24 at 12 months; peak levels: 8.06, 10.1, 7.28, and 4.48 mmol/L, respectively). In 44 patients, LA levels progressed spontaneously to normality within the first year of life. Three girls presented a slight and self-limited delay in psychomotor development, with LA peak levels of 7.3, 4.0, and 4.6 mmol/L. Only the gestational use of didanosine was associated with a higher risk of hyperlactatemia. Conclusions. In our series, almost half of the children (63 of 127) who were exposed to nucleoside analogues developed benign and self-limited hyperlactatemia. When symptomatic, nucleoside analogue–induced toxicity affected neurologic development.


Clinica Chimica Acta | 1998

Antioxidant status in hyperphenylalaninemia

Cristina Sierra; M. Antònia Vilaseca; Dolores Moyano; Nuria Brandi; Jaume Campistol; Nilo Lambruschini; Fco.José Cambra; Ramón Deulofeu; Aurea Mira

Abnormal oxidative stress was observed in some inborn errors of metabolism owing to the accumulation of toxic metabolites leading to excessive free radical production and to the influence of restricted diets on the antioxidant status. Erythrocyte antioxidant enzymes activities and tocopherol concentrations were measured in a group of phenylketonuric (n = 42) and mild-hyperphenylalaninemic (n = 28) patients compared with 45 age-matched controls. We also determined plasma selenium levels in these groups. We also evaluated the possible relationship between antioxidant status and neuropsychological disorders. Erythrocyte glutathione peroxidase (GSH-Px) activity was significantly lower (P < 0.001) in both phenylketonuric and mild-hyperphenylalaninemic patients compared with the control group, but no differences were observed between the two groups of patients. Neuropsychological disturbances were more frequent in the group of PKU patients with low GSH-Px activity than in PKU patients with normal GSH-Px. Low GSH-Px activity might be explained in phenylketonuria as a result of a selenium deficiency caused by a poor selenium intake or absorption, but not in mild hyperphenylalaninemic patients with free diet. Selenium levels were normal in both groups of patients, so low glutathione peroxidase activity in both phenylketonuric and hyperphenylalaninemic groups might be influenced by other factors, such as the consequences of an unbalanced amino acid profile, common to both conditions.


Human Mutation | 2009

Identification of novel mutations in the SLC25A15 gene in hyperornithinemia‐hyperammonemia‐homocitrullinuria (HHH) syndrome: A clinical, molecular, and functional study

Alessandra Tessa; Giuseppe Fiermonte; Carlo Dionisi-Vici; Eleonora Paradies; Matthias R. Baumgartner; Yin-Hsiu Chien; Carmela Loguercio; Hélène Ogier de Baulny; Marie Cecile Nassogne; Manuel Schiff; Federica Deodato; Giancarlo Parenti; S. Lane Rutledge; M. Antònia Vilaseca; Mariarosa A. B. Melone; Gioacchino Scarano; Luiz Aldamiz-Echevarria; G. T. N. Besley; J. H. Walter; Eugenia Martinez-Hernandez; Jose M. Hernandez; Ciro Leonardo Pierri; Ferdinando Palmieri; Filippo M. Santorelli

Hyperornithinemia‐hyperammonemia‐homocitrullinuria (HHH) syndrome is an autosomal recessive disorder of the urea cycle. With the exception of the French‐Canadian founder effect, no common mutation has been detected in other populations. In this study, we collected 16 additional HHH cases and expanded the spectrum of SLC25A15/ORC1 mutations. Eleven novel mutations were identified including six new missense and one microrearrangement. We also measured the transport properties of the recombinant purified proteins in reconstituted liposomes for four new and two previously reported missense mutations and proved that the transport activities of these mutant forms of ORC1 were reduced as compared with the wild‐type protein; residual activity ranged between 4% and 19%. Furthermore, we designed three‐dimensional (3D)‐modeling of mutant ORC1 proteins. While modeling the changes in silico allowed us to obtain new information on the pathomechanisms underlying HHH syndrome, we found no clear‐cut genotype–phenotype correlations. Although patient metabolic alterations responded well to low‐protein therapy, predictions concerning the long‐term evolution of HHH syndrome remain uncertain. The preference for a hepatic rather than a neurological presentation at onset also continues, largely, to elude us. Neither modifications in oxidative metabolism‐related energy, such as those expected in different mtDNA haplogroups, nor sequence variants in SLC25A2/ORC2 seem to be crucial. Other factors, including protein stability and function, and ORC1‐ORC2 structural interactions should be further investigated. Hum Mutat 0, 1–8, 2009.


Clinica Chimica Acta | 1997

Tocopherol in inborn errors of intermediary metabolism

Dolores Moyano; M. Antònia Vilaseca; Mercè Pineda; Jaume Campistol; Anna Vernet; Pilar Póo; Rafael Artuch; Cristina Sierra

Red blood cell tocopherol was measured in a group of 92 children with inborn errors of intermediary metabolism to evaluate the peroxidative damage in different mitochondrial and cytosolic defects, and to consider the need for treatment or vitamin supplementation. Tocopherol was determined by HPLC with UV detection. Results were expressed in nanomoles red blood cell tocopherol per gram protein. Significant differences (Mann-Whitney; P < 0.001) were found between tocopherol levels in untreated patients: 19 with mitochondrial defects versus 23 with cytosolic enzyme or transport defects, and versus 58 age-matched reference values. In conclusion, mitochondrial enzyme deficiencies, either amino and organic acidurias or defects of energy metabolism, seem to produce an excess of free radicals with the consequent utilization of tocopherol as antioxidant. This is not apparent in the cytosolic enzyme defects studied, whose tocopherol levels are in the normal range. Treatment with tocopherol completely corrects the deficient antioxidant status.


Brain & Development | 1995

An atypical French form of pyruvate carboxylase deficiency

Mercè Pineda; Jaume Campistol; M. Antònia Vilaseca; Paz Briones; Antonia Ribes; Teresa Temudo; Marti Pons; Victòria Cusí; Marie-Odile Rolland

A further case of pyruvate carboxylase deficiency, French type, with a particular clinical presentation and evolution is described. The initial neonatal symptoms started with respiratory distress, severe metabolic acidosis and a tendency to hypoglycemia. However, the clinical course was not rapidly deteriorating. At the age of 6 months he presented acute neurological symptoms, respiratory difficulty, lactic acidosis and hyperammonemia. Amino and organic acid abnormalities strongly suggested pyruvate carboxylase deficiency, which was confirmed by enzymatic studies in cultured fibroblasts and liver necropsy. Progressive deterioration and bronchopneumonia with cardiac failure and renal insufficiency led to death. Anatomic-pathologic studies revealed periventricular cysts and diffuse hypomyelination. Prenatal diagnosis of a further sibling was performed. The neonatal clinical presentation, biochemical abnormalities, and the presence of periventricular cysts suggested a French phenotype. However, the clinical course was less severe, suggesting a residual enzymatic activity and a possible milder mutation.


Clinical Chemistry and Laboratory Medicine | 2000

Personal experience with the application of carbohydrate-deficient transferrin (CDT) assays to the detection of congenital disorders of glycosylation.

Catrina Colomé; Imma Ferrer; Rafael Artuch; M. Antònia Vilaseca; Mercè Pineda; Paz Briones

Abstract Congenital disorders of glycosylation (CDG) are genetic multisystemic diseases due to various defects in the biosynthesis or processing of glycoproteins. Our aim is to present our experience in the selective screening of CDG syndrome in a paediatric population (421 patients) with clinical suspicion of the disease, analysing serum carbohydrate-deficient transferrin (CDT) by radioimmunoassay and/or immunoturbidimetry. We established the normal values for our paediatric population. The abnormal results were confirmed and classified by isoelectric focusing of serum sialotransferrins, and by enzymatic and molecular studies. We found 14 patients (3.3%) with abnormal serum CDT; 11 of them were classified as CDG type Ia (CDG-Ia) and the other three showed altered isoelectrofocusing patterns but remain untyped and are under investigation. In conclusion, both CDT assays proved to be useful tools for CDG screening. Isoelectric focusing is a simple procedure but it requires specific instruments that are not always available. Since the immunoturbidimetric procedure is commonly used to monitor for recent excessive alcohol consumption in clinical laboratories and does not require special equipment, it may also be reliably used to screen for CDG in children under clinical suspicion.


Journal of Molecular Medicine | 2001

Large de novo deletion in chromosome 12 affecting the PAH, IGF1, ASCL1, and TRA1 genes

Judith Mallolas; M. Antònia Vilaseca; Carlos Pavía; Nilo Lambruschini; Francisco José Cambra; Jaume Campistol; David Gómez; Ana Carrió; Xavier Estivill; Montserrat Milà

Phenylketonuria is one of the most common genetic diseases in humans, affecting 1 in 10,000 whites. Deletions are generally uncommon in genes in which no long highly homologous segments are present, and in phenylalanine hydroxylase (PAH) deficiency they represent only 5% of cases. We present the case of a girl affected by classical phenylketonuria who has been screened for mutations in the PAH gene. During the molecular study a large de novo deletion has detected in 12qter, including PAH, and the genes for insulin-like growth factor 1 (IGF1), human achaete-scute homolog 1 (ASCL1), and tumor rejection antigen (TRA1). The patient showed phenylketonuria, short stature, and pathological electro-oculography results in both eyes, with high affectation of the relative electrogenesis of the photoreceptor-pigment epithelium complex. She had previously been misdiagnosed as homozygous for the IVS8nt-7A-G mutation, instead of heterozygous for a mutation and a de novo deletion. As a result incorrect genetic counseling had been given. The deletion of the PAH, IGF1, and ASCL1 genes could explain the patients phenotype corresponding to a contiguous gene syndrome. We stress the relevance of polymorphic marker haplotype analysis and the importance of family study in genetic recessive diseases, such as phenylketonuria, to avoid incorrect diagnosis and genetic counseling.


Clinical Chemistry | 1997

Total Homocysteine in Pediatric Patients

M. Antònia Vilaseca; Dolores Moyano; Imma Ferrer; Rafael Artuch


European Journal of Paediatric Neurology | 2000

Anti-Epileptic drug treatment in children: Hyperhomocysteinaemia, B-Vitamins and the 677C→T Mutation of the Methylenetetrahydrofolate Reductase Gene

M. Antònia Vilaseca; Eugènia Monrós; Rafael Artuch; Catrina Colomé; Carme Farré; Carme Valls; Esther Cardo; Mercè Pineda


European Journal of Paediatric Neurology | 2001

Congenital disorders of glycosylation (CDG) may be underdiagnosed when mimicking mitochondrial disease

Paz Briones; M. Antònia Vilaseca; M. Teresa Garcı́a-Silva; Mercè Pineda; J. Colomer; Imma Ferrer; J Artigas; Jaak Jaeken; Amparo Chabas

Collaboration


Dive into the M. Antònia Vilaseca's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Paz Briones

Spanish National Research Council

View shared research outputs
Top Co-Authors

Avatar

Catrina Colomé

Hospital Sant Joan de Déu Barcelona

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Esther Cardo

University of Barcelona

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Aurea Mira

University of Barcelona

View shared research outputs
Top Co-Authors

Avatar

Carme Valls

Hospital Sant Joan de Déu Barcelona

View shared research outputs
Researchain Logo
Decentralizing Knowledge